Novavax posts positive preclinical results for flu/COVID-19 vaccine

By The Science Advisory Board staff writers

Novavax is highlighting positive preclinical results for a combination influenza/COVID-19 vaccine.

The vaccine is a combination of NanoFlu and the company's COVID-19 candidate NVX-CoV2373; results from the preclinical animal trial were published May 5 on bioRxiv. The study found that the combination elicited strong responses against both influenza A and B and protected against the SARS-CoV-2 virus, according to the firm. It expects to begin clinical studies of the combination by the end of this year.

NVX-CoV2373 is also being evaluated in two phase II trials, one in South Africa and one in the U.S. and Australia, as well as two phase III trials, one in the U.K. and another in the U.S. and Mexico, according to Novavax.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?